Liquidia to pay United Therapeutics $381 million to settle Yutrepia patent dispute
Liquidia agreed to pay approximately $380.7 million to United Therapeutics to resolve a years-long legal dispute over its lung disease drug Yutrepia, ending six lawsuits and removing major litigation risk. Liquidia shares surged 26% following the settlement announcement.
